The published Figure 2 reflected the sensitivity analysis for various percentages reduction in LDL-cholesterol with moderate-and high-intensity statin therapy rather than the revised sensitivity analysis with different percentages of patients on moderate-and high-intensity statins, as intended by the authors. The legend to Figure 2 read as follows: Figure 2 . Absolute risk reduction (ARR) in 10-year risk for atherosclerotic cardiovascular disease (ASCVD)10 and number needed-to-treat (NNT) to prevent an ASCVD event are depicted for adults with and without diabetes mellitus and with ASCVD10 ≥7.5%. The data points reflect changes in ARR and NNT as the proportion of individuals taking moderatedose (MD) and high-dose (HD) statins varies from 0% to 100% in 25% increments. Figure 2 has been replaced with a corrected figure, and the legend to Figure 2 has been corrected.
The authors regret the error. The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/5/8/ e003558.full ª 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
